The Efficacy of a Two-Fold Increase of H1-Antihistamine in the Treatment of Chronic Urticaria - the Vietnamese Experience by Tran Thi, Huyen et al.
 _______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2019 Jan 30; 7(2):259-263.                                                                                                                                                        259 
 
ID Design Press, Skopje, Republic of Macedonia 
Open Access Macedonian Journal of Medical Sciences. 2019 Jan 30; 7(2):259-263. 
Special Issue: Vietnamese Dermatology 
https://doi.org/10.3889/oamjms.2019.069 
eISSN: 1857-9655 
Clinical Science 
 
 
  
 
The Efficacy of a Two-Fold Increase of H1-Antihistamine in the 
Treatment of Chronic Urticaria - the Vietnamese Experience 
 
 
Huyen Tran Thi
1
, Lan Pham Thi
1
, Thuong Nguyen Van
1
, Phuong Pham Thi Minh
1
, Hao Nguyen Trong
2
, Tro Chau Van
3
, Sau 
Nguyen Huu
1
, Trang Trinh Minh
1
, Nghi Dinh Huu
1
, Tam Hoang Van
1
, Van Tran Cam
1
, My Le Huyen
1
, Khang Tran Hau
1
, 
Marco Gandolfi
4
, Francesca Satolli
4
, Claudio Feliciani
4
, Michael Tirant
5,6
, Aleksandra Vojvodic
7
, Torello Lotti
5
 
 
1
National Hospital of Dermatology and Venereology, Hanoi, Vietnam; 
2
HCMC Hospital of Dermato-Venereology, Ho Chi 
Minh City, Vietnam; 
3
Department of Dermatology, Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam; 
4
Unit of Dermatology, University of Parma, Parma, Italy; 
5
University of Rome G. Marconi, Rome, Italy; 
6
Psoriasis Eczema 
Clinic, Melbourne, Australia; 
7
Department of Dermatology and Venereology, Military Medical Academy of Belgrade, 
Belgrade, Serbia 
 
Citation: Tran Thi H, Pham Thi L, Van TN, Thi Minh PP, 
Nguyen Trong H, Chau Van T, Nguyen Huu S, Trinh Minh 
T, Dinh Huu N, Hoang Van T, Tran Cam V, Le Huyen M, 
Tran Hau K, Gandolfi M, Satolli F, Feliciani C, Tirant M, 
Vojvodic A, Lotti T. The Efficacy of a Two-Fold Increase 
of H1-Antihistamine in the Treatment of Chronic Urticaria - 
the Vietnamese Experience. Open Access Maced J Med 
Sci. 2019 Jan 30; 7(2):259-263. 
https://doi.org/10.3889/oamjms.2019.069 
Keywords: Chronic urticaria; Chronic idiopathic urticaria; 
Antihistamine; Fexofenadine; Levocetirizine 
*Correspondence: Marco Gandolfi. Unit of Dermatology, 
University of Parma, Parma, Italy. E-mail: 
marco.gandolfi5@gmail.com 
Received: 02-Jan-2019; Revised: 16-Jan-2019; 
Accepted: 17-Jan-2019; Online first: 28-Jan-2019 
Copyright: © 2019 Huyen Tran Thi, Lan Pham Thi, 
Thuong Nguyen Van, Phuong Pham Thi Minh, Hao 
Nguyen Trong, Tro Chau Van, Sau Nguyen Huu, Trang 
Trinh Minh, Nghi Dinh Huu, Tam Hoang Van, Van Tran 
Cam, My Le Huyen, Khang Tran Hau, Marco Gandolfi, 
Francesca Satolli, Claudio Feliciani, Michael Tirant, 
Aleksandra Vojvodic, Torello Lotti. This is an open-access 
article distributed under the terms of the Creative 
Commons Attribution-NonCommercial 4.0 International 
License (CC BY-NC 4.0) 
Funding: This research did not receive any financial 
support 
Competing Interests: The authors have declared that no 
competing interests exist 
 
 
 
 
 
Abstract 
BACKGROUND: Chronic urticaria, a mast cell-driven condition, is common, debilitating and hard to treat. H1-
antihistamines are the first line treatment of chronic urticaria, but often patients do not get satisfactory relief with 
the recommended dose. European guidelines recommend increased antihistamine doses up to four-fold.  
AIM: We conducted this study to evaluate the efficacy of increased H1-antihistamine doses up to two-fold in 
Vietnamese chronic urticaria patients. 
METHODS: One hundred and two patients with chronic urticaria were recruited for treatment with levocetirizine (n 
= 52) or fexofenadine (n = 50). Treatment started at the conventional daily dose of 5 mg levocetirizine or 180 mg 
fexofenadine for 2 weeks and then increased to 10 mg levocetirizine or 360 mg fexofenadine for 2 weeks if 
patients did not have an improvement in symptoms. At week 0, week 2 and week 4 wheal, pruritus, size of the 
wheal, total symptom scores, and associated side-effects were assessed. 
RESULTS: With the conventional dose, the total symptom scores after week 2 decreased significantly in both 
groups compared to baseline figures, i.e. 7.4 vs 2.3 for levocetirizine group and 8.0 vs 2.6 for fexofenadine group 
(p < 0.05). However, there were still 26 patients in each group who did not have improvements. Of these 26 
patients, after having a two-fold increase of the conventional dose, 11.5% and 38.5% became symptom-free at 
week 4 in levocetirizine group and fexofenadine group, respectively. At week 4 in both groups, the total symptom 
scores had significantly decreased when compared with those at week 2 (2.8 ± 1.5 versus 4.7 ± 1.6 in 
levocetirizine group; 2.1 ± 1.9 versus 5.1 ± 1.4 in fexofenadine group). In both groups, there was no difference in 
the rate of negative side effects between the conventional dose and the double dose. 
CONCLUSION: This study showed that increasing the dosages of levocetirizine and fexofenadine by two-fold 
improved chronic urticaria symptoms without increasing the rate of negative side effects. 
 
 
 
 
 
 
 
 
Introduction 
 
Urticaria is an allergic reaction of the skin 
capillaries to many endogenous or exogenous 
allergens. This disease can be characterised by the 
formation of wheals, angioedema or both and can 
disappear within 24 hours [1]. Patients with urticaria 
often experience a sensation of itching or burning 
which can interfere with daily life. Based on 
chronology, urticaria is divided into acute and chronic. 
As opposed to acute urticaria, chronic urticaria is 
defined by recurrent episodes occurring at least twice 
a week for 6 weeks, possibly lasting for many months, 
or many years [2], [3], [4]. Urticaria is also classified 
as spontaneous and inducible with and without any 
specific eliciting factor involved. Chronic urticaria 
substantially impacts on a patient’s quality of life with 
an effect on both physical and mental health. Studies 
have shown that health status scores in chronic 
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spontaneous urticaria patients are comparable to 
those with coronary artery disease [5].  
The exact cause of urticaria is unknown, but 
there are some factors contributing to the 
development of the disease. In urticaria, mast cells 
are activated, release histamine and other mediators, 
which result in vasodilatation, inflammatory 
recruitment cells, as well as sensory nerve activation. 
The therapeutic approach to chronic urticaria involves 
the identification and elimination of its underlying 
causes, the avoidance of eliciting factors, tolerance 
induction, and/or the use of pharmacological 
treatment to prevent mast cell mediator release and/or 
the effects of mast cell mediators [1]. The main option 
in therapies aimed at symptomatic relief is to reduce 
the effect of mast cell mediators such as histamine 
and others on the target organs. Many symptoms of 
urticaria are mediated primarily by the actions of 
histamine on H1-receptors located on endothelial cells 
(the wheal) and sensory nerves (neurogenic flare and 
pruritus). Thus, continuous treatment with H1-
antihistamines is of eminent importance in the 
treatment of urticaria. It is supported not only by the 
results of clinical trials but also by the mechanism of 
action of these medications [6], [7].  
There have been some studies on the 
effectiveness of antihistamine and other drugs in the 
treatment of chronic urticaria with varying results. 
Mainstay therapeutics are antihistamines, which in 
chronic urticaria, shows poor response rates when 
used in standard dosage. The up-dosing of 
antihistamines to four-fold does improve the response 
rate [8], [1]. In Vietnam, conventional doses of H1-
antihistamine are widely used in the treatment of 
chronic urticaria, and in practice, the majority of 
patients have a good response to conventional doses. 
However, difficult-to-treat chronic urticaria patients 
remain a challenge and data on doses used for 
Vietnamese patients is scarce.  
We conducted this study to evaluate the 
efficacy and safety of a two-fold increase of H1-
antihistamine (fexofenadine and levocetirizine) in the 
treatment of chronic urticaria.  
 
 
Methods 
 
From March to August 2013 we recruited 102 
patients with chronic urticaria, aged 12 years and 
above at the National Hospital of Dermato-
venereology. Exclusion criteria were: (1) urticaria with 
glottis oedema or accompanied by diarrhoea; (2) 
physical urticarial; (3) presence of other diseases 
such as liver, kidney, endocrine, psychiatric or 
systemic disease; (4) pregnant and lactating women; 
(5) women taking contraceptive drugs; (6) patients 
who had taken antihistamines or steroids in the past 2 
weeks; (7) the use of any other drugs during the 
treatment period; (8) patients with biochemical 
abnormalities. Biochemistry was tested at week 0 and 
week 4 including urea, creatinine, glucose, liver 
enzymes, cholesterol, and triglycerides. 
One hundred and two patients with chronic 
urticaria were randomly recruited into 2 groups: 1) 
levocetirizine group (52 patients) and 2) fexofenadine 
group (50 patients). Treatment started at the 
conventional dose in each group. 5 mg levocetirizine 
daily for the levocetirizine group and 180 mg 
fexofenadine daily for the fexofenadine group. After 2 
weeks if the symptoms were persistent, the patients 
were given a double dose.  
The patients underwent clinical examinations. 
Each of the following symptoms was scored according 
to the Urticaria Activity Score (UAS) 4 [9] at week 0, 
week 2 and week 4.  
Pruritus score: none: 0 points; mild: 1 point 
(present but not annoying or troublesome); moderate: 
2 points (troublesome but did not interfere with sleep); 
severe: 3 points (severe pruritus, which is 
troublesome enough to interfere with normal daily 
activities or sleep) 
Wheal score: none: 0 points; 1-19 wheals/24 
hours: 1 point; 20-50 wheals/24 hours: 2 points; more 
than 50 wheals/24 hours or large confluent areas of 
wheals: 3 points. 
We also scored the size of the biggest wheal 
as following: none: 0 points; less than 1.25 cm in 
diameter: 1 point; 1.25-2.5 cm in diameter: 2 points; 
more than 2.5 cm in diameter: 3 points. 
Total symptom score: 0 points: free of 
symptoms; 1-3 points: mild; 4-6 points: moderate; 7-9 
points: severe. 
This study used SPSS statistical software 
(version 16.0) with the use of a t-test for quantitative 
variables and a χ
2 
test for qualitative variables.  
This study was approved by the hospital 
ethics board of National Hospital of Dermatology and 
Venereology in 2013. The investigator ensured that 
the study was conducted by the Declaration of 
Helsinki. 
 
 
Results 
 
The background characteristics of patients in 
the two groups were not significantly different as 
shown in Table 1.  
The mean age of our patients was 36.2 years 
(aged 14-65) for the levocetirizine group and 39 years 
(aged 12-68) for the fexofenadine group. None of the 
patients was at a mild level at week 0. There were 
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69.2% female patients in the levocetirizine group and 
64% in the fexofenadine group. The majority of 
patients (73.2% in levocetirizine group and 46% in 
fexofenadine group) had suffered from urticaria from 6 
weeks to 1 year.  
Table 1: The background characteristics of the patients 
 Levocetirizine group 
(n = 52) 
Fexofenadine group 
(n = 50) 
Age 
Mean 
Range 
 
36.2 ± 0.5 
14-65 
 
39 ± 0.7 
12-68 
≤ 20 7 (13.5%) 10 (20%) 
21-40 29 (55.8%) 25 (50%) 
41-60 14 (26.9%) 14 (28%) 
≥ 61 2 (3.8%) 1 (2%) 
Sex   
Male 16 (30.8%) 18 (36%) 
Female 36 (69.2%) 32 (64%) 
The duration of disease   
6 week-1 year 32 (73.2%) 23 (46.0%) 
1-5 years 16 (30.8%) 14 (28.0%) 
> 5 year 4 (7.7%) 13 (26.0%) 
 
At week 0, total symptom scores were 7.4 ± 
1.3 in the levocetirizine group and 8.0 ± 1.0 in the 
fexofenadine group. At week 2 (2 weeks after 
treatment with a conventional dose) the total symptom 
scores 2.3 ± 2.6 and 2.6 ± 2.8 respectively as shown 
in Table 2 had decreased significantly when 
compared with those at week 0.  
Table 2: The symptom scores of the two group treated with a 
conventional dose at week 0 and week 2 
 Levocetirizine (n = 52) p Fexofenadine (n = 50) p 
 Week 0 Week 2  Week 0 Week 2  
Pruritus 2.7 ± 0.8 0.9 ± 0.9 < 0.05 2.9 ± 0.2 1.0 ± 1.1 < 0.05 
Wheal 2.2 ± 0.6 0.8 ± 0.9 < 0.05 2.5 ± 0.7 0.9 ± 0.9 < 0.05 
Size of wheal 2.7 ± 0.5 0.7 ± 0.9 < 0.05 2.5 ± 0.7 0.8 ± 0.9 < 0.05 
Total symptom 
score 
7.4 ± 1.3 2.3 ± 2.6 < 0.05 8.0 ± 1.0 2.6 ± 2.8 < 0.05 
 
However, at this point, there were still 26 
patients in each group who were still not symptom-
free. Their total symptom scores were 4.7 ± 1.6 in the 
levocetirizine group and 5.1 ± 1.4 in the fexofenadine 
group (p > 0.05) as shown in Table 3. These patients 
were treated with a double dose for 2 weeks. The 
patients who had recovered maintained their 
conventional daily dose and left our trial. 
At week 4, we evaluated the remaining 26 
patients who were treated with a double dose in each 
group. The result showed that total symptom scores 
were significantly reduced (Table 3). 
Table 3: The symptom scores of the two groups treated with a 
double dose at week 2 and week 4 
 Levocetirizine (n = 26) p Fexofenadine (n = 26) p 
 Week 2 Week 4  Week 2 Week 4  
Pruritus 1.7 ± 0.6 0.9 ± 0.7 < 0.05 1.9 ± 0.7 0.7 ± 0.9 < 0.05 
Wheal 1.5 ± 0.8 1.0 ± 0.7 < 0.05 1.7 ± 0.6 0.7 ± 0.6 < 0.05 
Size of wheal 1.4 ± 0.7 0.9 ± 0.4 < 0.05 1.5 ± 0.7 0.7 ± 0.6 < 0.05 
Total symptom 
score 
4.7 ± 1.6 2.8 ± 1.5 < 0.05 5.1 ± 1.4 2.1 ± 1.9 < 0.05 
 
With 2.8 ± 1.5 in the levocetirizine group and 
2.1 ± 1.9 in the fexofenadine group. Between the two 
groups, there was no statistically significant difference 
(p > 0.05). In the levocetirizine group at week 4, 
11.5% of the patients had a resolution of symptoms, 
61.5% with a mild form of the disease, 26.9% 
moderate and no patient was severe. In the 
fexofenadine group at week 38.5% of patients had a 
resolution of symptoms, the proportion of patients with 
a mild level was 26.9% (versus 23.0% before 
treatment), and a moderate level was 34.6% (versus 
57.8% before treatment). There was no patient with a 
severe form of the disease at week 4 (versus 19.2% 
before treatment) as shown in Figure 1.  
 
Figure 1: Severity of disease in the two groups at week 2 and week 
4; A) Levocetirizine group; B) Fexofenadine group 
 
The proportion of undesirable side effects at a 
conventional dose of the levocetirizine group was 
9.6% and for the fexofenadine group 8.0%. When the 
dose was doubled the proportions of side effects were 
11.5% and 10.2% respectively for the two groups. 
Overall the most common side effects were 
drowsiness and fatigue. Results concluded that no 
patients had any biochemical abnormalities after 4 
weeks of treatment (at least with the level of urea, 
creatinine and liver enzymes). 
 
 
Discussion 
 
This study of H1-antihistamines doses of 102 
patients with chronic urticaria provided three important 
results. H1-antihistamine at a conventional dose 
affected recovery in about half of the patients. In the 
remaining difficult-to-treat patients a two-fold dose of 
H1- antihistamines improved symptoms of urticaria 
significantly. This study also found that levocetirizine 
seemed to be slightly more effective than 
fexofenadine, thought this didn't prove to be 
statistically significant. 
H1-antihistamine affected improving the 
symptoms of all chronic urticaria patients. More than 
half of the patients recovered from all symptoms on 5 
mg levocetirizine or 180 mg fexofenadine per day. 
These patients continued to maintain this therapy for a 
long period after the trial. Though many patients still 
had symptoms after 2 weeks of treatment with a 
conventional dose. Pre-treatment, most had suffered 
from the disease for over 6 months, and the severity 
of urticaria was moderate to severe (results not 
shown). 
Given that histamine mediates almost all 
symptoms of urticaria through H1-receptors located on 
nerves and endothelial cells, the European Academy 
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of Allergy and Clinical Immunology (EAACI)/Global 
Allergy and Asthma European Network 
(GA2LEN)/European Dermatology Forum (EDF) 
guidelines recommend that the first line of treatment 
should be with nonsedating H1-antihistamine [10]. 
Trials support the use of this drugs in most forms of 
urticaria [10] howerver in a study of 390 patients, only 
about 44% responded well to this treatment: 29% 
were discharged asymptomatic with another 15% only 
showing a partial relief of symptoms [11]. This raises 
some questions as to the need for an increased dose 
of H1-antihistamine also whether individual patients 
respond better to one antihistamine over another [12].  
A two-fold increase in the dose of histamine 
H1 reduced the symptoms in patients not responding 
to conventional doses. General concerns over 
increasing the dose are the negative side effects 
associated with the drug. However, this study found 
that side effects were not different between a 
conventional dose and an increased dose. Overall the 
most common side effects were drowsiness and 
fatigue. Second-generation H1-antihistamines (such 
as levocetirizine and fexofenadine) represent a 
substantial therapeutic advance and often show a lack 
of cardiotoxicity, an absence of cholinergic side 
effects and display minimal sedation [12]. Increasing 
the dose of antihistamines is a good solution in 
difficult-to-treat urticaria, replacing the need to switch 
to other drugs such as systemic corticosteroids. With 
an increased dose of both levocetirizine and 
fexofenadine, there was a significant improvement in 
the quality of life of the patient.  
European guidelines allow a four-fold 
increase to the normal dose of H1-antihistamines [1] 
however as there are no published studies in Vietnam 
on an increased dose we increased the dose only 2 
times as a precaution. After 2 weeks of double dose 
therapy, there were still many long-term and severe 
patients who were still not fully asymptomatic. From 
the fifth week, these patients were treated with 
alternative antihistamines before attempting other 
drugs such as montelukast, cyclosporin and systemic 
corticosteroid. The Staevska et al., (2010) study of 80 
patients with difficult-to-treat urticaria showed that the 
25 patients who failed to respond to 20 mg 
desloratadine, 7 became symptom-free on 20 mg 
levocetirizine [12]. As mentioned, in previous studies 
of urticaria other proinflammatory mediators such as 
interleukine-4 and leukotriene may contribute to 
clinical and histological images of the disease [13]. 
Mast and basophilic cells of volunteers without 
urticaria were incubated with serum from idiopathic 
chronic urticarial patients and produced interleukine-4 
and leukotriene. These two mediators can cause 
perivascular infiltration of the inflammatory cells that 
affect skin cells. This infiltration creates the difference 
between a histological lesion of acute urticaria and 
that of physical urticaria. The use of antihistamines 
cannot cure all the symptoms of urticaria however 
several clinical trials using montelukast, in 
combination with antihistamines (cetirizine, 
fexofenadine, loratadine or desloratadine) revealed 
better results than those using antihistamines alone 
(improving symptoms and the quality of life). 
Interestingly, when used as a standalone treatment, 
monotherapy leukotriene antagonists have no effect 
on chronic urticaria [13]. 
Levocetirizine and fexofenadine have been 
known to have an equal effect in improving the 
symptoms of chronic urticaria. However, in this trial at 
week 4, the rate of symptomatic relief was higher in 
the levocetirizine group than in the fexofenadine 
group. Different H1-antihistamines may have different 
effects in the treatment of urticaria. In a study of 886 
patients, results revealed that levocetirizine 5 mg was 
significantly more efficacious than desloratadine 5 mg 
in the treatment of chronic urticaria [14]. Though it 
must be noted that fexofenadine is less dependent on 
liver function so it can be prescribed to patients with 
hepatic diseases. 
Of course, there were some limitations to be 
noted in this study. Firstly, the effectiveness was 
evaluated based on clinical improvement, which can 
often be subjective between investigators and 
patients. Secondly, the study’s duration was only 4 
weeks; a long-term follow-up study is lacking thus far. 
Finally, UAS was used to evaluate the severity of 
chronic urticaria on the day in which the patients 
checked into the hospital, UAS7 was not used (which 
evaluates the last seven days). USA7 is clearly more 
precise than UAS but this information was not 
available at the time and therefore could not be used 
in this study. 
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